Experimental Trials. Oslin ExTENd Late Trigger for Nonresponse 8 wks Response TDM + Naltrexone CBI Random assignment: CBI +Naltrexone Nonresponse Early.

Slides:

Advertisements

Similar presentations

Piloting and Sizing Sequential Multiple Assignment Randomized Trials in Dynamic Treatment Regime Development 2012 Atlantic Causal Inference Conference.

Advertisements

1 Designing A Study Adapted from The Research Methods Knowledge Base, William Trochim (2006). & Methods for Social Researchers in Developing Counries,

1 Timing and Duration of Relapse Prevention Trials in Psychiatric New Drug Development David Michelson, M.D. Executive Director, Neuroscience Medical Research.

Treatment Effect Heterogeneity & Dynamic Treatment Regime Development S.A. Murphy.

11 Confidence Intervals, Q-Learning and Dynamic Treatment Regimes S.A. Murphy Time for Causality – Bristol April, 2012 TexPoint fonts used in EMF. Read.

Using Clinical Trial Data to Construct Policies for Guiding Clinical Decision Making S. Murphy & J. Pineau American Control Conference Special Session.

Adaptive Treatment Strategies in the Addictions: Current Examples and Future Directions James R. McKay, Ph.D. Professor of Psychology in Psychiatry University.

Experimenting to Improve Clinical Practice S.A. Murphy AAAS, 02/15/13 TexPoint fonts used in EMF. Read the TexPoint manual before you delete this box.:

Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.

1 Dynamic Treatment Regimes Advances and Open Problems S.A. Murphy ICSPRAR-2008.

Causal Inference and Alternative Explanations S.A. Murphy Univ. of Michigan May, 2004.

1 Developing Adaptive Treatment Strategies using MOST Experimental Designs S.A. Murphy Univ. of Michigan Dallas: December, 2005.

Methodology for Adaptive Treatment Strategies for Chronic Disorders: Focus on Pain S.A. Murphy NIH Pain Consortium 5 th Annual Symposium on Advances in.

SMART Designs for Constructing Adaptive Treatment Strategies S.A. Murphy 15th Annual Duke Nicotine Research Conference September, 2009.

1 Dynamic Treatment Regimens S.A. Murphy PolMeth XXV July 10, 2008.

SMART Designs for Developing Adaptive Treatment Strategies S.A. Murphy K. Lynch, J. McKay, D. Oslin & T.Ten Have CPDD June, 2005.

1 A Prediction Interval for the Misclassification Rate E.B. Laber & S.A. Murphy.

SMART Experimental Designs for Developing Adaptive Treatment Strategies S.A. Murphy NIDA DESPR February, 2007.

1 A Confidence Interval for the Misclassification Rate S.A. Murphy & E.B. Laber.

Planning Survival Analysis Studies of Dynamic Treatment Regimes Z. Li & S.A. Murphy UNC October, 2009.

SMART Experimental Designs for Developing Adaptive Treatment Strategies S.A. Murphy RWJ Clinical Scholars Program, UMich April, 2007.

1 Meeting the Future in Managing Chronic Disorders: Individually Tailored Strategies S.A. Murphy Herbert E. Robbins Collegiate Professorship in Statistics.

1 SMART Designs for Developing Adaptive Treatment Strategies S.A. Murphy K. Lynch, J. McKay, D. Oslin & T.Ten Have UMichSpline February, 2006.

Methodology for Adaptive Treatment Strategies R21 DA S.A. Murphy For MCATS Oct. 8, 2009.

1 Possible Roles for Reinforcement Learning in Clinical Research S.A. Murphy November 14, 2007.

1 A Prediction Interval for the Misclassification Rate E.B. Laber & S.A. Murphy.

Susan Murphy, PI University of Michigan Acknowledgements: MCAT network and NIH The Goal To facilitate methodological collaborations necessary for producing.

Experiments and Dynamic Treatment Regimes S.A. Murphy At NIAID, BRB December, 2007.

1 Machine/Reinforcement Learning in Clinical Research S.A. Murphy May 19, 2008.

Adaptive Treatment Strategies S.A. Murphy CCNIA Proposal Meeting 2008.

Adaptive Treatment Strategies S.A. Murphy Workshop on Adaptive Treatment Strategies Convergence, 2008.

Practical Application of Adaptive Treatment Strategies in Trial Design and Analysis S.A. Murphy Center for Clinical Trials Network Classroom Series April.

Adaptive Treatment Design and Analysis S.A. Murphy TRC, UPenn April, 2007.

Learn to Predict “Affecting Changes” in Software Engineering Xiaoxia Ren Dec. 8, 2003.

Behavior Strategies in Diet Control The Challenge and the Cure Dr Abeer Al Saweer Consultant Family Physician, Diabetologist Kingdom of Bahrain.

Sequential, Multiple Assignment, Randomized Trials and Treatment Policies S.A. Murphy UAlberta, 09/28/12 TexPoint fonts used in EMF. Read the TexPoint.

SUBSTANCE USE DISORDERS GENERAL METHODS OF TREATMENT Inpatient Detoxification and Rehabilitation Outpatient Individual, Couple, or Family Counseling Self-help.

Section 3. Double Blind - Neither the subjects nor the people working with them know which treatment each subject is receiving Block Design - A block.

What is a Clinical Trial (alpha version) John M. Harris Jr., MD President Medical Directions, Inc.

1 Trauma Systems Therapy for Adolescent Substance Abuse (TST-SA) Liza Suárez, Ph.D. Glenn Saxe, MD Center for Anxiety and Related Disorders Center for.

SMART Case Studies Module 3—Day 1 Getting SMART About Developing Individualized Adaptive Health Interventions Methods Work, Chicago, Illinois, June

Sequential, Multiple Assignment, Randomized Trials and Treatment Policies S.A. Murphy MUCMD, 08/10/12 TexPoint fonts used in EMF. Read the TexPoint manual.

Prevention of Recurrent Venous Thromboembolism N Engl J Med Apr ;348(15) : PREVENT (Warfarin) Trial.

Raymond F. Anton, MD for The COMBINE Study Research Group

Assessment of Treatment Results: Designed to evaluate the Patient’s Opinion of their response to Acupuncture Rx. u Following your Acupuncture Treatment.

Is the Continual Reassessment Method Superior to the Standard “3+3” dose escalation scheme? Alexia Iasonos 1 Elyn R. Riedel 1, David.

1 SMART Designs for Developing Adaptive Treatment Strategies S.A. Murphy K. Lynch, J. McKay, D. Oslin & T.Ten Have NDRI April, 2006.

Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.

Background and Rationale for COMBINE A Multisite Clinical Trial Sponsored by National Institute on Alcohol Abuse and Alcoholism NIH, DHHS Margaret E. Mattson,

A POST-MARKETING EVALUATION OF SAFETY CAMPTOSAR + 5-FU/LV FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER A POST-MARKETING EVALUATION OF SAFETY.

Designing An Adaptive Treatment Susan A. Murphy Univ. of Michigan Joint with Linda Collins & Karen Bierman Pennsylvania State Univ.

European Patients’ Academy on Therapeutic Innovation Special Populations.

SMART Trials for Developing Adaptive Treatment Strategies S.A. Murphy Workshop on Adaptive Treatment Designs NCDEU, 2006.

Date of download: 6/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Prospective, Randomized, Double-blind Comparison.

Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.

Copyright © 1998 American Medical Association. All rights reserved.

Copyright © 2008 American Medical Association. All rights reserved.

ASSIGNMENT NO.-2.

CNSL 562 Innovative Education--snaptutorial.com

ورشة بعنوان استراتيجيات تعديل السلوك بين النظرية والتطبيق

Updates on Obesity Treatment:

استراتيجيات تعديل السلوك بين النظرية والتطبيق

الفصل الرابع بـــــــرامج التأهيل

Preventing Clinical Events in PAH

Issues in TB Drug Development: A Regulatory Perspective

Control for the difference in the number of trials removed between ADHD and healthy subjects based on behavior. Figures attached to Comment #9 by Reviewer.

Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.

Assessed for eligibility N = 15593

Treatment appointment

Presentation transcript:

Experimental Trials

Oslin ExTENd Late Trigger for Nonresponse 8 wks Response TDM + Naltrexone CBI Random assignment: CBI +Naltrexone Nonresponse Early Trigger for Nonresponse Random assignment: Naltrexone 8 wks Response Random assignment: CBI +Naltrexone CBI TDM + Naltrexone Naltrexone Nonresponse

Pellman ADHD Study B. Begin low dose medication 8 weeks Assess- Adequate response? B1. Continue, reassess monthly; randomize if deteriorate B2. Increase dose of medication with monthly changes as needed Random assignment: B3. Add behavioral treatment; medication dose remains stable but intensity of bemod may increase with adaptive modifications based on impairment No Yes A. Begin low-intensity behavior modification 8 weeks Assess- Adequate response? A1. Continue, reassess monthly; randomize if deteriorate A2. Add medication; bemod remains stable but medication dose may vary Random assignment: A3. Increase intensity of bemod with adaptive modifications based on impairment Yes No Random assignment:

Proposed Study for Drug-Addicted Pregnant Women rRBT 2 wks Response rRBT tRBT Random assignment: rRBT Nonresponse tRBT Random assignment: aRBT 2 wks Response Random assignment: eRBT tRBT rRBT Nonresponse